• It’s today’s top story: Pfizer-Wyeth deal falls through! Kindler to resign!!! [Bloomberg]

• Solvay looking for someone to buy its pharma business…yawn, who isn’t? Get in line guys. [WSJ Health Blog]

• Biomarin gives rights to Riquent back to La Jolla, legal reasons I guess. [BizJournals]

• Teva gets approval for generic YAZ. What will Lo say? [Genetic Engineering & Biotechnology News]

• Bioxel Pharma goes under. I know, I know: who’s Bioxel? [TechFinance]

• Ambrx, another protein therapeutic maker, raises $10M from 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences. [peHUB]

• Iceland’s deCODE Genetics may go under; nation’s financial crisis partly to blame? [TimesOnline]

• Altea Therapeutics in $46M deal with Eli Lilly and Amylin Pharmaceuticals for exenatide patch. [FierceBiotech]

• Par Pharmaceuticals acquires rights to MDRNA osteoporosis drug and Nascobol from QOL. [Xconomy], [Forbes]

Image from ucdavis

Related Posts